Talphera (TLPH)
NASDAQ:TLPH
Want to see TLPH full AI Analyst Report?
TLPH Stock Chart & Stats
$1.10
-$0.04(-6.10%)
At close: 4:00 PM EST
$1.10
-$0.04(-6.10%)
Day’s Range― - ―
52-Week Range$0.38 - $1.57
Previous CloseN/A
Volume42.81K
Average Volume (3M)2.97M
Market Cap
$40.24M
Enterprise Value$12.92M
Total Cash (Recent Filing)$21.11M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 19, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding51,899,647
10 Day Avg. Volume675,544
30 Day Avg. Volume2,969,035
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)2.84
Price to Sales (P/S)1726.72
P/FCF Ratio-4.25
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue12.92K
Enterprise Value/Gross Profit12.92K
Enterprise Value/Ebitda-0.83
Forecast
1Y Price Target
$3.17Price Target Upside187.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet BufferA zero debt position and positive equity (~$18.5M) deliver structural financial flexibility, reducing near-term refinancing pressure and lowering fixed-cost obligations. This balance-sheet strength gives management runway to prioritize clinical milestones without immediate debt servicing risk.
Clinical Enrollment MomentumSurpassing the 50% enrollment milestone and clear enrollment plan materially de-risks the development timeline. Sustained site activation and KOL support improve likelihood of timely completion and regulatory submission, underpinning the company’s pathway to potential commercialization and revenue generation.
Fast Readout Design & Dosing SimplicityA 24-hour primary endpoint and demonstrated rapid dosing stability enable quick, definitive topline results, shortening development lead times. Faster readouts reduce time-to-decision for regulators and investors and lower the calendar risk of prolonged trials, strengthening the program’s commercial timing profile.
Bears Say
Persistent Cash Burn & Minimal RevenueOperating with almost no revenue while incurring multi‑million dollar annual losses and negative operating cash flow is a durable structural weakness. Continued burn without a revenue base forces recurring financing, limits strategic optionality, and elevates dilution and execution risk over several quarters.
Reliance On Conditional FinancingMaterial reliance on milestone‑contingent tranches ties the company’s funding to execution timing and outcomes. If milestones slip or conditions aren’t met, capital shortfalls could delay regulatory work or force unfavorable financing, increasing the probability of dilution or operational pauses.
Nasdaq Minimum Bid-Price NoticeA listing deficiency introduces structural governance and capital-raising risk: remediation may require corporate actions (reverse split), distract management, and impair liquidity or investor access. Persistent noncompliance could ultimately threaten market access and strategic flexibility.
Talphera News
TLPH FAQ
What was Talphera’s price range in the past 12 months?
Talphera lowest stock price was $0.38 and its highest was $1.57 in the past 12 months.
What is Talphera’s market cap?
Talphera’s market cap is $40.24M.
When is Talphera’s upcoming earnings report date?
Talphera’s upcoming earnings report date is Aug 19, 2026 which is in 77 days.
How were Talphera’s earnings last quarter?
Talphera released its earnings results on May 13, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.067 by $0.027.
Is Talphera overvalued?
According to Wall Street analysts Talphera’s price is currently Undervalued.
Does Talphera pay dividends?
Talphera does not currently pay dividends.
What is Talphera’s EPS estimate?
Talphera’s EPS estimate is -0.06.
How many shares outstanding does Talphera have?
Talphera has 51,899,647 shares outstanding.
What happened to Talphera’s price movement after its last earnings report?
Talphera reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.067. Following the earnings report the stock price went down -0.444%.
Which hedge fund is a major shareholder of Talphera?
Currently, no hedge funds are holding shares in TLPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Talphera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.17 (187.88% Upside)
$3.17 (187.88% Upside)
Crowd Wisdom
Negative
Last 7 Days ▲ 2.0%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.75%
12-Months-Change
Fundamentals
Return on Equity
-92.98%
Trailing 12-Months
Asset Growth
101.10%
Trailing 12-Months
Company Description
Talphera
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.
TLPH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and operational momentum: enrollment has surpassed the 50% milestone, sites and KOLs reported favorable feedback on dosing simplicity and stability, and management expects a rapid top-line read in H2 2026 with a PMA plan for 2027. However, the company faces higher operating expenses and depends on two conditional financing tranches (~$16M) to fund the path to potential approval, with enrollment variability and financing contingency as primary risks. Overall, positive progress is balanced against execution and financing risk, but the highlights outweigh the lowlights.View all TLPH earnings summariesTLPH Stock 12 Month Forecast
Average Price Target
$3.17
▲(187.88% Upside)
Technical Analysis
Ownership Overview
5.94% Insiders
1.48% Mutual Funds
38.89% Other Institutional Investors
52.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---